Related Experiment Videos
Biologic therapy for psoriasis: a brief history, II.
W D Tutrone1, M H Kagen, J Barbagallo
1Department of Dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, New York, New York 10025, USA.
Cutis
|January 5, 2002
Summary
This review covers interleukin 10 (IL-10) and CTLA4Ig therapies. It also examines four leading psoriasis treatments: infliximab, etanercept, efalizumab, and alefacept.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Psoriasis is a chronic autoimmune disease.
- Current treatments have limitations.
- Novel therapeutic targets are under investigation.
Purpose of the Study:
- To review advanced immunomodulatory agents for psoriasis.
- To discuss the therapeutic potential of IL-10, T-cell receptor mimic peptides, and CTLA4Ig.
- To evaluate four promising biologic therapies for psoriasis.
Main Methods:
- Literature review of existing research.
- Analysis of preclinical and clinical data.
- Synthesis of information on novel psoriasis treatments.
Main Results:
- Interleukin 10 (IL-10) shows potential for immune modulation.
- T-cell receptor mimic peptides offer targeted immune suppression.
- CTLA4Ig acts as a co-stimulatory blockade agent.
- Infliximab, etanercept, efalizumab, and alefacept are effective in clinical trials.
Conclusions:
- IL-10, T-cell receptor mimic peptides, and CTLA4Ig represent novel therapeutic avenues.
- Biologics like infliximab, etanercept, efalizumab, and alefacept are crucial for psoriasis management.
- Further research is needed to optimize these treatments for long-term efficacy and safety.